Notice of Intent to Sole Source Invetech GMP Korus SUS Kits
ID: 25-001317Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/e05fc3a9fb66498d9f619bff2e83c976/view
Timeline
    Description

    The National Institutes of Health (NIH) intends to award a fixed-price purchase order for GMP Korus SUS Kits to Invetech Inc., as part of a sole source procurement. The kits are essential for the Department of Transfusion Medicine, Center Cellular Engineering, which manufactures human cells and tissue-based products for clinical protocols in transplantation and gene therapy. Invetech Inc. is the only known source capable of providing these proprietary kits that are compatible with the Invetech Korus™ Counterflow Elutriation System, which is critical for the department's operations. Interested parties may submit capability statements to Sheri Eiri at sheri.eiri@nih.gov by November 14, 2024, at noon EST for consideration in this procurement process.

    Point(s) of Contact
    Sheri Eiri
    000000000
    sheri.eiri@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source Invetech GMP Korus SUS Kits
    Currently viewing
    Presolicitation
    Similar Opportunities
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    BD Biosciences Proprietary Instrumentation Package and Reagent Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure a proprietary instrumentation package and reagent kits from Becton, Dickinson & Company for the Department of Laboratory Medicine. This acquisition aims to secure essential supplies, including instrument rentals and quality control materials, necessary for the operation of the Hematology Flow Cytometry Service, which plays a critical role in patient care and research. The procurement is vital for maintaining the laboratory's capacity to deliver timely and accurate results, as the specified reagent kits are uniquely compatible with the existing BD Rhapsody™ single cell analysis system. Interested parties may submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by November 14, 2024, at 6:30 AM EST, as this is a presolicitation notice and not a request for quotations.
    Revio reagent kit, 24pack All reagents for sequenc
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure the Revio reagent kit, which includes a 24-pack of all reagents necessary for sequencing 24 Revio SMRT Cells. This solicitation aims to acquire essential laboratory supplies that are critical for advanced genomic sequencing applications. The Revio reagent kit plays a vital role in supporting research and development in the field of genomics and personalized medicine. Interested vendors can reach out to Dorothy L. Maxwell at dorothy.maxwell@nih.gov or call 301-827-7729 for further details regarding the procurement process.
    NOI Cytiva Sepax C-Pro Cell Processing Systems Software Upgrade
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed price contract for a software upgrade on two Cytiva Sepax C-Pro Cell Processing Systems. The objective of this procurement is to enhance the functionality of these systems, which are critical for the Department of Transfusion Medicine, thereby reducing the need for alternative devices and associated maintenance costs. The software upgrades are necessary to ensure the full operational capabilities of the existing equipment, as Cytiva-Global Life Sciences Solutions USA LLC is the sole supplier of the proprietary software required for this task. Interested parties must submit capability statements by November 14, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov for consideration.
    Notice of Intent to Sole Source; Monument Medical
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to QuVA Pharma, Inc. for the procurement of compounded intravenous (IV) narcotics for patient care at the NIH Clinical Center. This acquisition aims to secure sterile compounded products that meet the quality standards necessary for ongoing patient treatment, as QuVA Pharma is the sole distributor of these specific IV narcotics in the U.S. market. Interested parties are invited to express their interest and capabilities regarding this procurement, with comments due by November 15, 2024, at 10 AM EST, directed to Kristin Nagashima at kristin.nagashima@nih.gov.
    Sources Sought-BioFire Reagents and Test Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is conducting a Sources Sought announcement to identify potential qualified small businesses capable of supplying BioFire Defense reagents and test kits. The NIH's Department of Laboratory Medicine requires these reagents for their BioFire FilmArray analyzers, which are essential for the rapid detection of infectious agents from clinical samples, thereby facilitating timely treatment. Interested vendors must submit their company information, including a capability statement, by 12:00 PM EST on November 7, 2024, to Sheri Eiri at sheri.eiri@nih.gov, as the government will not reimburse any costs associated with this request.
    Notice of Intent to Sole Source - Biosearch Technologies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) intends to negotiate a sole source contract with Biosearch Technologies, Inc. for the production of proprietary PCR kits essential for the Laboratory Response Network (LRN). The procurement aims to ensure a consistent supply of reagents necessary for detecting biothreat agents and emerging infectious diseases, which are critical for national preparedness and response capabilities. These kits, which must comply with FDA quality standards, are vital for high-security laboratories and are designed to identify various bioterrorism agents. Interested parties may submit capability statements or proposals to Matthew Nelson at mnelson2@cdc.gov by November 7, 2024, at 3:30 PM EST for consideration.
    Gore Medical branded stents (Brand Name restriction)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, National Institutes of Health seeks to procure specific medical devices for use in interventional radiology procedures. These are brand-restricted items, with the National Institute of Health specifying Gore Medical branded stents. The scope of work involves supplying several variants of two medical devices: Viatorr Tips Endo CX and Viabahn BX Balloon Expander Endo. The Viatorr Tips are measured in millimeters and vary in length, while the Viabahn BX Balloon Expanders are used in catheterization procedures. The medical devices are intended for minimally invasive procedures. The bill of materials provided outlines the exact models and quantities sought. Offerors must provide the following: 1 unit of Model PTB8105275, ID 00733132635016 - 8-10mmX5cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model PTB8107275, ID 00733132635030 - 8-10mmX7cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model PTB8108275, ID 00733132635047 - 8-10mmX8cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model BXB083901A, ID 00733132658718 - 8MMX39MM 7Fr 80CM Cath RP VIABAHN BX BALLOON EXP ENDO 1 unit of Model BXB085901A, ID 00733132658732 - 8MMX59MM 7Fr 80CM Cath RP VIABAHN BX BALLOON EXP ENDO Eligible applicants should be well-established surgical and medical instrument manufacturers (NAICS code 339112) with the ability to deliver the specified devices promptly. The evaluation of quotes will consider technical capability, price, and past performance. Quotes should be submitted to Lu Chang at lu-chang.lu@nih.gov by 5:00 PM EST on 08/01/2024, including the RFQ number (RFQ-CC-24-010258) in the subject line. Further inquiries can be directed to the same email address. This opportunity is a combined synopsis and solicitation issued under FAR Subpart 12.6. The resulting contract will be a firm fixed-price order.
    Notice of Intent to Sole Source INTERCEPT Blood System for Platelets
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, intends to award a sole source Firm-Fixed-Price contract to CERUS Corporation for the procurement of the INTERCEPT Blood System for Platelets. This system is a commercial-off-the-shelf (COTS) product essential for ensuring the safety and efficacy of platelet transfusions, which is critical for patient care in military medical facilities. The contract will cover a base year from January 1, 2025, to December 31, 2025, with an estimated total value of $210,816.00, and will include two option years. Interested parties may submit evidence demonstrating that competition would be beneficial to the Government, but the decision to proceed with a competitive procurement rests solely with the Government. For inquiries, contact Cynthia Scharnowske at cynthia.e.scharnowske.civ@health.mil, and please reference "Notice of Intent Submission 12160537" in the subject line.
    BIO-RAD LABORATORIES, INC. CSP, QX200 DIGITAL PCR W/ADG OS DIGITAL PCR SYSTEMS W/AUTO DG SERVICE CONTRACT
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is planning to award a sole source fixed-price contract to Bio-Rad Laboratories, Inc. for a service contract related to two QX200 AutoDG ddPCR Systems. The contract will cover a twelve-month base year with four additional option years, focusing on essential maintenance and support services to ensure compliance with FDA regulations and optimal operational performance of the equipment. These systems are critical for assessing gene modification efficiency in cellular therapy products, which directly impacts treatment decisions and patient outcomes. Interested parties may express their interest and capabilities to Tasha Lowe at lowet2@mail.nih.gov by November 9, 2024, at 12 PM, as the government retains discretion over the procurement process.